| 1 |
34837284 |
10.1111/cas.15224 |
2022 |
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. |
MEF2B |
| 2 |
35240014 |
10.4143/crt.2022.017 |
2022 |
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. |
MEF2B |
| 3 |
35317330 |
10.14740/wjon1436 |
2022 |
Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. |
MEF2B |
| 4 |
35322462 |
10.1111/his.14652 |
2022 |
Epstein-Barr virus infection patterns in nodular lymphocyte-predominant Hodgkin lymphoma. |
MEF2B |
| 5 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
MEF2B |
| 6 |
33959502 |
10.3389/fonc.2021.638897 |
2021 |
c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. |
MEF2B |
| 7 |
34418874 |
10.1016/j.jmgm.2021.108009 |
2021 |
Systematic transition modeling analysis in the MEF2B-DNA binding interface due to Y69H and K4E variants. |
MEF2B |
| 8 |
35528192 |
10.1158/2767-9764.crc-21-0022 |
2021 |
The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways. |
MEF2B |
| 9 |
31423576 |
10.1111/bjh.16159 |
2020 |
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. |
MEF2B |
| 10 |
31850910 |
10.1097/PAI.0000000000000813 |
2020 |
Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. |
MEF2B |
| 11 |
31914533 |
10.3760/cma.j.issn.0529-5807.2020.01.008 |
2020 |
[Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance]. |
MEF2B |
| 12 |
32738045 |
10.1093/nar/gkaa642 |
2020 |
Landscape of DNA binding signatures of myocyte enhancer factor-2B reveals a unique interplay of base and shape readout. |
MEF2B |
| 13 |
33045225 |
10.1016/j.humpath.2020.09.014 |
2020 |
The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. |
MEF2B |
| 14 |
33211828 |
10.1182/bloodadvances.2020002944 |
2020 |
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. |
MEF2B |
| 15 |
33232656 |
10.1016/j.molcel.2020.10.036 |
2020 |
Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. |
MEF2B |
| 16 |
30446717 |
10.1038/s41374-018-0152-2 |
2019 |
MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type. |
MEF2B |
| 17 |
31403034 |
10.3389/fonc.2019.00683 |
2019 |
Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. |
MEF2B |
| 18 |
29122756 |
10.1182/blood-2017-08-799080 |
2018 |
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. |
MEF2B |
| 19 |
29309299 |
10.1097/PAS.0000000000001015 |
2018 |
Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas. |
MEF2B |
| 20 |
29477338 |
10.1016/j.jmb.2018.02.012 |
2018 |
The Cancer Mutation D83V Induces an α-Helix to β-Strand Conformation Switch in MEF2B. |
MEF2B |
| 21 |
30006595 |
10.1038/s41598-018-25712-1 |
2018 |
Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. |
MEF2B |
| 22 |
30205047 |
10.1016/j.ccell.2018.08.006 |
2018 |
MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. |
MEF2B |
| 23 |
27389057 |
10.1038/leu.2016.175 |
2017 |
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. |
MEF2B |
| 24 |
28116089 |
10.1186/s40425-016-0207-0 |
2017 |
It's a long way to the top (if you want to personalize immunotherapy). |
MEF2B |
| 25 |
28851661 |
10.1016/j.humpath.2017.08.015 |
2017 |
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. |
MEF2B |
| 26 |
29222279 |
10.1182/asheducation-2017.1.358 |
2017 |
Follicular lymphoma: are we ready for a risk-adapted approach? |
MEF2B |
| 27 |
26468528 |
10.1128/JVI.02318-15 |
2016 |
Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. |
MEF2B |
| 28 |
26631611 |
10.1158/1078-0432.CCR-15-2023 |
2016 |
Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. |
MEF2B |
| 29 |
27166360 |
10.1182/blood-2016-02-699520 |
2016 |
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. |
MEF2B |
| 30 |
27198204 |
10.1038/leu.2016.135 |
2016 |
Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. |
MEF2B |
| 31 |
27224912 |
10.18632/oncotarget.9500 |
2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. |
MEF2B |
| 32 |
25769544 |
10.3324/haematol.2014.120048 |
2015 |
BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2. |
MEF2B |
| 33 |
26089142 |
10.1007/s00428-015-1796-6 |
2015 |
Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. |
MEF2B |
| 34 |
26229090 |
10.1158/2159-8290.CD-15-0370 |
2015 |
Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. |
MEF2B |
| 35 |
26245647 |
10.1038/ncomms8953 |
2015 |
MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. |
MEF2B |
| 36 |
26256760 |
10.1016/S1470-2045(15)00169-2 |
2015 |
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. |
MEF2B |
| 37 |
24942943 |
10.3960/jslrt.54.23 |
2014 |
Molecular pathogenesis of follicular lymphoma. |
MEF2B |
| 38 |
23292937 |
10.1073/pnas.1205299110 |
2013 |
Genetic heterogeneity of diffuse large B-cell lymphoma. |
MEF2B |
| 39 |
23382691 |
10.1371/journal.pgen.1003225 |
2013 |
Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. |
MEF2B |
| 40 |
23407552 |
10.1182/blood-2013-01-478834 |
2013 |
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. |
MEF2B |
| 41 |
23974956 |
10.1038/ni.2688 |
2013 |
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. |
MEF2B |
| 42 |
24052547 |
10.1182/blood-2013-04-496893 |
2013 |
EZH2 mutations are frequent and represent an early event in follicular lymphoma. |
MEF2B |
| 43 |
24145436 |
10.1073/pnas.1314608110 |
2013 |
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. |
MEF2B |
| 44 |
22343534 |
10.1073/pnas.1121343109 |
2012 |
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. |
MEF2B |
| 45 |
21796119 |
10.1038/nature10351 |
2011 |
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. |
MEF2B |
Datasets
Models
